Sophie L. V. M. Stroeks

Sophie L. V. M. Stroeks

Auto-generated profile, based on publicly available information

Sophie L. V. M. Stroeks

Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands (A.B.M.H., S.L.V.M.S., N.J.B., M.F.G.H.M.V., S.R.B.H., J.A.J.V.).

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
MSMaurits Sikking
Maurits Sikking
SSSophie L. V. M. Stroeks
Sophie L. V. M. Stroeks
OWOlivia J. Waring
Olivia J. Waring
MHMichiel T. H. M. Henkens
Michiel T. H. M. Henkens
NRNiels P. Riksen
Niels P. Riksen
JVJob Verdonschot
Job Verdonschot
Clonal hematopoiesis of indeterminate potential (CHIP) is a common bone marrow abnormality induced by age‐related DNA mutations, which give rise to proinflammatory immune cells. These immune cells exacerbate atherosclerotic cardiovascular disease and may induce or accelerate heart failure. The mechanisms involved are complex but point toward a central role for proinflammatory macrophages and an inflammasome‐dependent immune response (IL‐1 [interleukin‐1] and IL‐6 [interleukin‐6]) in the atherosclerotic plaque or directly in the myocardium. Intracardiac inflammation may decrease cardiac function and induce cardiac fibrosis, even in the absence of atherosclerotic cardiovascular disease. The pathophysiology and consequences of CHIP may differ among implicated genes as well as subgroups of patients with heart failure, based on cause (ischemic versus nonischemic) and ejection fraction (reduced ejection fraction versus preserved ejection fraction). Evidence is accumulating that CHIP is associated with cardiovascular mortality in ischemic and nonischemic heart failure with reduced ejection fraction and involved in the development of heart failure with preserved ejection fraction. CHIP and corresponding inflammatory pathways provide a highly potent therapeutic target. Randomized controlled trials in patients with well‐phenotyped heart failure, where readily available anti‐inflammatory therapies are used to intervene with clonal hematopoiesis, may pave the way for a new area of heart failure treatment. The first clinical trials that target CHIP are already registered.

15 June 2023 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
MSMaurits Sikking
Maurits Sikking
SSSophie L.V.M. Stroeks
Sophie L.V.M. Stroeks
FMFederica Marelli-Berg
Federica Marelli-Berg
SHStephane Heymans
Stephane Heymans
BLBurkhard Ludewig
Burkhard Ludewig
JVJob Verdonschot
Job Verdonschot
• Myocardial fibrosis represents an unmet medical need, and its regulation by immunological mechanisms is increasingly evident. • Emerging immunotherapies ameliorate myocardial fibrosis either by targeting cardiac fibroblast directly or via the immune system. • Targeted immunotherapeutic approaches may reduce the risk of heart failure while mitigating potential safety concerns.

11 August 2025 in European Heart Journal
Verified
Journal Article
Open access
RJRenee Johnson
Renee Johnson
RFRobert A Fletcher
Robert A Fletcher
SPStacey Peters
Stacey Peters
MOMonique Ohanian
Monique Ohanian
MSMagdalena Soka
Magdalena Soka
DFDiane Fatkin
Diane Fatkin
Background and Aims: Truncating variants in the TTN gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) but also occur as incidental findings in the general population. This study investigated factors associated with the clinical manifestation of TTNtv. Methods: An international multicentre retrospective observational study was performed in families with TTNtv-related DCM. Shared frailty models were used to estimate associations of variant characteristics with lifetime risk of DCM, and logistic regression to estimate odds ratios (ORs) for individual-level clinical risk factor profiles (cardiac conditions, cardiovascular comorbidities, lifestyle) and DCM. Results: A total of 3158 subjects in 1043 families with TTNtv-related DCM were studied. TTNtv-positive subjects were 21-fold more likely to develop DCM [OR, 21.21; 95% confidence interval (CI), 14.80–30.39]. Disease onset was earlier in males, but was similar for TTNtv of different types and locations. The presence of clinical risk factors was associated with earlier DCM onset (OR, 3.41; 95% CI, 2.06–5.64), with a prior history of atrial fibrillation having a two-fold increased odds of DCM (OR, 2.05; 95% CI, 1.27–3.32). The prevalence of clinical risk factors increased with age; however, the strength of the DCM association was greatest for young-onset (<30 years) disease (OR, 4.75; 95% CI, 2.35–9.60). Administration of beta-adrenergic receptor or renin-angiotensin system-blocking drugs prior to overt DCM was associated with 87% reduced odds of DCM (OR, .13; 95% CI, .08–.23). Conclusions: Disease onset in TTNtv-associated familial DCM is dependent on individual patient context and is potentially modifiable by risk factor management and prophylactic therapeutic intervention.

1 April 2023 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
SSSophie L.V.M. Stroeks
Sophie L.V.M. Stroeks
Ida Gjervold LundeIda Gjervold Lunde
Ida Gjervold Lunde
DHDebby M.E.I. Hellebrekers
Debby M.E.I. Hellebrekers
GCGodelieve R.F. Claes
Godelieve R.F. Claes
HWHiroko Wakimoto
Hiroko Wakimoto
JVJob Verdonschot
Job Verdonschot
Background: Dilated cardiomyopathy (DCM) was considered a monogenetic disease that can be caused by over 60 genes. Evidence suggests that the combination of multiple pathogenic variants leads to greater disease severity and earlier onset. So far, not much is known about the prevalence and disease course of multiple pathogenic variants in patients with DCM. To gain insight into these knowledge gaps, we (1) systematically collected clinical information from a well-characterized DCM cohort and (2) created a mouse model. Methods: Complete cardiac phenotyping and genotyping was performed in 685 patients with consecutive DCM. Compound heterozygous digenic (LMNA [lamin]/titin deletion A-band) with monogenic (LMNA/wild-type) and wild-type/wild-type mice were created and phenotypically followed over time. Results: One hundred thirty-one likely pathogenic/pathogenic (LP/P) variants in robust DCM-associated genes were found in 685 patients with DCM (19.1%) genotyped for the robust genes. Three of the 131 patients had a second LP/P variant (2.3%). These 3 patients had a comparable disease onset, disease severity, and clinical course to patients with DCM with one LP/P. The LMNA/Titin deletion A-band mice had no functional differences compared with the LMNA/wild-type mice after 40 weeks of follow-up, although RNA-sequencing suggests increased cardiac stress and sarcomere insufficiency in the LMNA/Titin deletion A-band mice. Conclusions: In this study population, 2.3% of patients with DCM with one LP/P also have a second LP/P in a different gene. Although the second LP/P does not seem to influence the disease course of DCM in patients and mice, the finding of a second LP/P can be of importance to their relatives.

1 August 2022 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
MHMichiel T.H.M. Henkens
Michiel T.H.M. Henkens
SSSophie L.V.M. Stroeks
Sophie L.V.M. Stroeks
ARAnne Raafs
Anne Raafs
MSMaurits Sikking
Maurits Sikking
JTJasper Tromp
Jasper Tromp
JVJob Verdonschot
Job Verdonschot

12 September 2025 in European Journal of Heart Failure
Verified
Journal Article
Open access
SSSophie L.V.M. Stroeks
Sophie L.V.M. Stroeks
PWPing Wang
Ping Wang
MMMarco Merlo
Marco Merlo
SMSteven Muller
Steven Muller
APAlessia Paldino
Alessia Paldino
JVJob Verdonschot
Job Verdonschot
Aims: Dilated cardiomyopathy (DCM) has a monogenic aetiology in up to 40% of patients. Understanding the spectrum of genotype–phenotype associations in DCM is crucial for risk stratification and personalized treatment. We aimed to (i) characterize genotype-specific features, (ii) evaluate whether phenotype-based clustering reflects underlying genotype, and (iii) compare the prognostic value of genotype- versus phenotype-based approaches. Methods and results: A multicentre cohort of 534 DCM patients with a (likely) pathogenic variant were grouped by genotype (genotype-first approach) and clustered by clinical phenotype (phenotype-first approach). We compared clinical characteristics, identified genotype–phenotype associations, and evaluated outcomes, including all-cause mortality, heart failure hospitalization, heart transplantation, and malignant ventricular arrhythmias. Using the genotype-first approach, significant genotype–phenotype associations were found for 10 genes. FLNC, LMNA, DSP, and PLN variants were linked to arrhythmias. BAG3, TNNT2, DMD, and TTN were associated with increased cardiac volumes and decreased left ventricular ejection fraction (LVEF). Clustering identified four phenotypic clusters: (1) young, moderately reduced LVEF; (2) arrhythmias, moderate reduced LVEF; (3) low LVEF; (4) arrhythmias, low LVEF. There were no clear correlations between phenotypic clusters and genotype. The genotype-first approach showed that LMNA, FLNC, and BAG3 variants had the highest risk for heart failure and arrhythmogenic adverse outcomes. The phenotype-first approach indicated that clusters 3 and 4 were associated with the worst prognosis. Overall, genotype was the strongest predictor of outcome. Conclusions: Patients with a genetic form of DCM exhibit clinical and genetic heterogeneity. Genotype-based risk stratification is more accurate compared to a phenotype-first approach, highlighting the importance of broad genetic screening among patients with DCM. Additionally, gene-specific risk prediction should become more prominent in current guidelines on management of genetic DCM patients.